Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

Michael P. Curry, Jacqueline G. O’Leary, Natalie Bzowej, +19

New England Journal of Medicine

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins

Heather L. Wiegand, Brian Doehle, Hal P. Bogerd, +1

The EMBO Journal

IL-1β Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease

Amina Negash, Hilario J. Ramos, Nanette Crochet, +8

PLoS Pathogens

Liver FibrosisImmunologyImmune RegulationPathologyImmunologic Mechanism +27

Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels

Sharon M. Moe, Danxia Duan, Brian Doehle, +2

Kidney International

InflammationHuman Blood VesselsBone Morphogenic ProteinMedicinePhysiology +8

A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor

Hal P. Bogerd, Brian Doehle, Heather L. Wiegand, +1

Proceedings of the National Academy of Sciences

Molecular VirologyHuman RetrovirusPathogenesisImmunologyAntiviral Response +12

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

Marc Bourlière, Jean-Pierre Bronowicki, Victor de Lédinghen, +24

The Lancet Infectious Diseases

HepatologyViral HepatitisAntiviral Drug DevelopmentHcv Genotype 1Hepatitis +7

Overexpression of Exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs

Rui Yi, Brian Doehle, Yi Qin, +2

RNA

Mirna FunctionEngineeringGeneticsShort Hairpin RnasEnhances Rna Interference +14

Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif

Brian Doehle, Alexandra Schäfer, Bryan R. Cullen

Virology

Human RetrovirusImmunologyPharmacologyHiv-1 InfectivityVirology +9

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Christoph Sarrazin, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, +13

Gastroenterology

Hcv Ns5aHealth SciencesViral HepatitisAntiviral TherapyHepatitis +9

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

Stefan Zeuzem, Masashi Mizokami, Stephen Pianko, +17

Journal of Hepatology